Pomegra
Quest Diagnostics Stock Falls 5% on Medicare Lab Fee Cuts
Why is Quest Diagnostics stock down today?
Quest Diagnostics (DGX) fell 5.1% to $233 on Tuesday and Labcorp (LH) dropped 3.3% after CMS proposed cutting 2027 Medicare lab reimbursement rates by up to 15%, a $90–$100 million hit to operating income.
Key numbers
| DGX Stock Decline | -5.1%vs. +42.4% YTD gain |
|---|---|
| LH Stock Decline | -3.3%vs. +34.6% YTD gain |
| Max Annual CMS Rate Cut | 15%/yreach year 2027 through 2029 |
| Medicare vs. Private Payors | ~16% aboveMedicare currently overpays vs. private rates |
| Est. Annual Taxpayer Savings | $1BCMS estimate from rate alignment |
| Evercore Adj. Op. Income Impact | $90–$100Mper company in 2027 |
What happened
Quest Diagnostics (DGX) fell 5.1% to $233 on Tuesday and Labcorp (LH) dropped 3.3% after CMS proposed cutting 2027 Medicare lab reimbursement rates by up to 15%, a $90–$100 million hit to operating income. CMS published preliminary 2027 Clinical Laboratory Fee Schedule rates on September 21, noting that Medicare currently pays about 16% more than private insurers for the same services. The proposed cuts — capped by law at 15% per year — could run through 2029 and would save taxpayers an estimated $1 billion annually. Evercore estimated the 2027 impact at $90–$100 million in adjusted operating income per company, calling it a low-to-mid single-digit earnings-per-share drag and a multi-year Medicare pricing headwind for both companies.
Why it matters
Lab stocks like Quest Diagnostics matter to investors because Medicare is the largest single customer for routine blood tests, chemistry panels, and DNA diagnostics — and lower government payments flow almost directly to profits. What makes this different from past adjustments is that the law allows CMS to cut rates by up to 15% per year from 2027 through 2029, compounding the pressure for three straight years before rates can stabilize. Patients' out-of-pocket costs do not immediately change, but the cuts squeeze labs that process millions of Medicare tests every year.
Who this affects
- MarketbearishMedium impact
- Lab-sector stocks broadly sold off on Medicare rate-cut news.
- CompanybearishHigh impact
- DGX and LH face $90–$100M operating income cuts in 2027.
- CompetitorsbearishMedium impact
- All labs face the same Medicare cuts; no competitive shift.
- IndustrybearishHigh impact
- Multi-year Medicare lab cuts reshape lab-testing industry economics.
Quest Diagnostics vs. Labcorp, Sonic Healthcare
How we got here
CMS releases preliminary 2027 CLFS proposing up to 15% cuts across lab tests.
DGX falls 5.1% and LH drops 3.3% as markets react to CMS announcement.
Evercore estimates $90–$100M adjusted operating income hit per lab company in 2027.
CMS 30-day public comment period closes; industry may challenge cut size.
New CLFS rates take effect; further 15% cuts possible in 2028 and 2029.
What to watch
- CMS finalizes 2027 CLFS rates in November; any softening would lift lab stocks.2026-11-01
- Q3 2026 earnings calls: DGX and LH will quantify exact Medicare revenue exposure.Q4 2026
- Industry comment letters before October 21 could narrow the scale of final cuts.2026-10-21
Educational content only. Not investment advice.
More briefsAll briefs →
Vicor Stock Jumps 10% After Doubling Q3 Revenue Guidance
Vicor (VICR) doubled its Q3 growth forecast to over 20% after four AI companies signed power-delivery deals.
On Holding Stock Jumps 13% on Zurich Investor Day
On Holding (ONON) surges on CHF 5.6 billion 2029 target, $1 billion buyback, and football and golf entry.
McDonald's Stock Falls 5% on $8.5B ArchIQ Drive-Through Plan
McDonald's (MCD) posts its worst one-day drop in six years as Burger King same-store sales outrun it 10-to-1.